Page 39 - Sun Pharma News Today

Analysts expect the sentiment in the market to continue to remain positive on the back of rate cut predictions by Fed Vice Chair Jefferson, Nvidias stock surge, and Indias projected FY25 GDP growth of 6.5 percent.

XLRI Jamshedpur records 100 percent placement, highest package Rs 75 lakh | Education News | The Avenue Mail

Indian drugmakers are developing their versions of Novo Nordisks weight-loss treatment, Wegovy, aiming to capitalize on the growing weight-loss market, expected to reach $100 billion a year by the end of the decade. Companies like Sun Pharma, Cipla, Dr Reddys, and Lupin are working on Wegovy alternatives as Novo Nordisk struggles to meet global demand.

Indian pharma companies have started developing their own versions of Novo Nordisk's wildly in demand Wegovy.

BNP prefers Sun Pharma and JB Chemicals in the pharma space and while it likes Apollo Hospitals Enterprise and Metropolis Healthcare Ltd in the healthcare services.

While Novo Nordisk A/S NVO faces challenges in meeting the global demand for its highly sought-after weight-loss treatment, Wegovy, Indian drugmakers see an…

Indian drugmakers aiming to grab a slice of the burgeoning weight-loss treatment sales pie, both at home and abroad, have begun developing their own versions of Novo...

Nifty on Thursday ended 162 points higher to form a long bull candle with a long lower shadow on the daily charts as the short-term trend of Nifty turned up sharply after a small decline.

Indian pharmaceutical giants, including Sun Pharma and Cipla, seize the opportunity to develop affordable versions of Novo Nordisk's Wegovy weight-loss treatment. With patents set to expire by 2026-2032, these generics aim to address India's rising obesity and diabetes concerns, anticipating substantial market growth in the next decade.

Pharmaceutical manufacturers in India are looking to cash in on the weight loss injection craze by making their own version of Wegovy — but they'll have to compete with all the marketplaces selling it off-brand if they do. As Reuters reports, the weight loss market is ripe for new blood considering that Novo Nordisk, the maker […]